Impax Laboratories Inc

Impax Laboratories — Q2 2017 Earnings Presentation

24 slides from Impax Laboratories's earnings presentation, Aug 9, 2017

  1. Slide 1: Second Quarter 2017 Results and Business Update

    1 Second Quarter 2017 Results and Business Update August 9, 2017

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and

  3. Slide 3: Presentation Overview

    3 Presentation Overview Paul Bisaro – President & Chief Executive Officer  2Q 2017 Results  Business Update Bryan Reasons – Senior Vice President, Chief Financial Officer  2Q 2017 Financial Review Paul Bisaro  2017 Financial Guidance  Path Forward

  4. Slide 4: Paul Bisaro, President & CEO

    4 Paul Bisaro President & CEO

  5. Slide 5: Solid Second Quarter 2017 Performance

    5 Solid Second Quarter 2017 Performance $173 $184 $202 2Q16 1Q17 2Q17 $41 $32 $39 2Q16 1Q17 2Q17 $0.21 $0.11 $0.18 2Q16 1Q17 2Q17 Revenues $ millions Adjusted EBITDA $ millions Adjusted EPS Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results •

  6. Slide 6: Generics Business Second Quarter Highlights

    6 Generics Business Second Quarter Highlights Second Quarter • Approved and launched first-to-market generic Vytorin® › Captured more than 40% share on launch • Continued growth of epinephrine auto-injector › 11% revenue growth over 2Q16 › 46% revenue growth over 1Q17 Post Second Quarter Events • Ge

  7. Slide 7: Specialty Business Second Quarter Highlights

    7 • 27% revenue growth over 2Q16 • 10% sequential revenue growth over 1Q17 • Evaluating impact of marketing programs • Revenue down 7% compared to 2Q16 • 25% sequential revenue growth over 1Q17 • Slowing growth rate due to additional competition • Short-term Albenza supply disruption in May impacted

  8. Slide 8: Pre-2017 Announced Initiatives

    8 Pre-2017 Announced Initiatives Achieved Initiatives Completed Closure of Middlesex manufacturing site Mid-2017 Closure of Philadelphia packaging facility 2016 Restructure Technical Operations and R&D 2015 Delivering on plan designed to improve efficiencies and profitability; provide resources to s

  9. Slide 9: 2017 Announced Initiatives

    9 2017 Announced Initiatives Ongoing Initiatives Completion Timing Consolidation of all generic R&D to Hayward, CA Completed mid-2017 Closure of Middlesex packaging site Completion by 1Q18 Rationalizing generic portfolio to eliminate low-value products Completion by 1Q18 Strategic alternatives for T

  10. Slide 10: Continuing to Expand Pipeline Opportunities

    10 Continuing to Expand Pipeline Opportunities Generic R&D Specialty Pharma R&D IPX203 Carbidopa-Levodopa  Phase 2b study  Multiple dose study in patients with advanced Parkinson’s disease  Readout of Phase 2b expected during the third quarter of 2017  Evaluating additional internal and external

  11. Slide 11: Bryan Reasons, Chief Financial Officer

    11 Bryan Reasons Chief Financial Officer

  12. Slide 12: Generic Division 2Q 2017 Results

    12 Generic Division 2Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 2Q 2017 1Q 2017 Change 2Q/1Q 2Q 2016 Change 2Q/2Q GENERIC DIVISION Total Revenues $150.9 $134.1 12% $121.7 24% GAAP Gross Margin 28% (6%) -- 31%

  13. Slide 13: Specialty Pharma Division 2Q 2017 Results

    13 Specialty Pharma Division 2Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 2Q 2017 1Q 2017 Change 2Q/1Q 2Q 2016 Change 2Q/2Q SPECIALTY PHARMA DIVISION Total Revenues $51.2 $50.3 2% $50.9 1% GAAP Gross Margin 59

  14. Slide 14: Consolidated 2Q 2017 Results

    14 Consolidated 2Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions, except per share amounts 2Q 2017 1Q 2017 Change 2Q/1Q 2Q 2016 Change 2Q/2Q EBITDA $16.6 ($30.2) 155% $23.4 (29%) Adjusted EBITDA $39.2 $31.9 23% $4

  15. Slide 15: Paul Bisaro, President & CEO

    15 Paul Bisaro President & CEO

  16. Slide 16: Reaffirmed 2017 EPS Guidance

    16 Reaffirmed 2017 EPS Guidance **Excludes new cost savings initiatives as outlined on slide 9. The Company’s full year 2017 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, inventory levels, and the anticipated timing of future

  17. Slide 17: Path Forward

    17 Path Forward • Generics: Continuing internal R&D investment and external R&D license efforts • Specialty: Continuing focus on Movement Disorders pipeline and opportunistically in-license external opportunities Invest in Organic Growth • Maintain high level of Quality and Compliance • Achieve supe

  18. Slide 18: Second Quarter 2017 Results and Business Update Q&A Session

    18 Second Quarter 2017 Results and Business Update Q&A Session August 9, 2017

  19. Slide 19: ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities

    19 ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities Source of sales data: IMS NPS June 2017; Pipeline data as of August 2, 2017 1 Launched authorized generic in April 2016 Disclosed Pending ANDAs Generic Product Name Brand IMS Sales Potential Launch Timing FTM Opport

  20. Slide 20: GAAP to Adjusted Results Reconciliation

    20 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development expenses, and adjusted selling, general and administrative expenses. (Unaudi

  21. Slide 21: GAAP to Adjusted Net Income Reconciliation

    21 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, In thousands, except per share and per share data) June 30, March 31, June 30, 2017 2017 2016 Net loss (20,417)$ (98,431)$ (2,701)$ Adjusted to add (deduct): Amortizatio

  22. Slide 22: GAAP to Adjusted EBITDA Reconciliation

    22 GAAP to Adjusted EBITDA Reconciliation Refer to the Second Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. The following table reconciles reported net loss to adjusted EBITDA. (Unaudited, In thousands) June 30, M

  23. Slide 23: Generic Division GAAP to Adjusted Results Reconciliation

    23 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and income (loss) from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, In

  24. Slide 24: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    24 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from operations.

Impax Laboratories — Q2 2017 Earnings Presentation on 6ix